Journal ArticleOPEN ACCESS

Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial

  • Loi S
  • Schmid P
  • Aktan G
  • et al.
Annals of Oncology (2019) 30 iii2
DOI: 10.1093/annonc/mdz095.003
N/ACitations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Presented at the San Antonio Breast Cancer Symposium (SABCS) 2018 Congress; December 4-8, 2018; San Antonio, Texas

Cite

CITATION STYLE

APA

Loi, S., Schmid, P., Aktan, G., Karantza, V., & Salgado, R. (2019). Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial. Annals of Oncology, 30, iii2. https://doi.org/10.1093/annonc/mdz095.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free